Aarti Drugs Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/odc08pou2wby7zu3a2ai0dhz.pdf

Key Takeaways


Margin Pressure: The Quarter's Dominant Story

Adhish Patil: "We firmly believe that most of the headwinds are transient in nature rather than structural and hopefully it will improve soon."

Demand & Volume Dynamics

Adhish Patil: "More than margins we should try to focus on the absolute EBITDA numbers in shorter-term like this."

Capex & Capacity Build-Out


Competitive Position & China

Harit Shah: "Overall scenario if you are efficiently producing any product we can always compete China that is our philosophy we feel that we can always compete China basically."

Guidance & Commitments

CommitmentSpecificsTimeline
Margin normalizationNormalized margins once input price volatility stabilizesFrom H2 FY23 onwards
Margin impact persistsInflationary pressure impact extends into part of Q2Q2 FY23
Cost-led margin recovery~0.5% EBITDA margin recovery (~₹2–2.5 Cr) through cost reductionNot specified
Specialty chemicals contributionMeaningful revenue contribution from Tarapur brownfieldH2 FY23 onwards
Greenfield API commissioningMain plant at Tarapur greenfield API facility commissionedBy end of FY23
Full-year capex₹250–350 CrFY23
Peak debt-to-equity~0.7–0.78, then declining each quarterPeak during capex cycle
Oncology facility revenue startNew formulation oncology facility begins contributing revenuesNext financial year
Oncology facility full potential₹200–250 Cr revenues~1.5–2 years from start
Metformin capacity2,000 tons per month12–18 months
Specialty chemicals capex revenue~₹600 Cr sales from ~₹250 Cr capex~1 year to complete
Full-year tax rate~25%FY23
New capacity breakevenUtilization rises and capacities contribute to profitWithin 1 year post-commissioning

Key Metrics

MetricQ1 FY23
Standalone revenue₹551.4 cr, +9% YoY
Consolidated revenue growth+7% YoY
Domestic revenue growth (standalone)~3% YoY
Exports revenue growth (standalone)~23% YoY
Specialty chemicals and intermediates revenue₹56.8 cr, +21% YoY
Formulation segment revenue₹85 cr, -2% YoY
Formulation EBITDA margin15%, up from 6.7% YoY
Formulation PBT margin~14%, up from ~5.8% YoY
Formulation PBT~₹12 cr
Debt-to-equity ratio0.51
Total consolidated debt~₹541 cr, of which ~₹187 cr long-term
Peak debt-to-equity expected~0.7 to 0.78
Peak debt expected~₹700 cr (per an analyst's math)
Capex incurred in Q1₹35 cr
Planned capex for FY2023₹250 to 350 cr
Metformin capacity1,200 tons per month
Metformin capacity utilization (FY2022)~mid-60s%
Forex impact on costs~₹4 cr
Power and coal cost rate increase impact~₹8 cr (₹1.5 cr power, ₹6.5 cr coal)
Exports volume growth~2% to 3%
Domestic business on one-month delivery terms~80% of domestic, which is two-thirds of total business
Raw material imports vs indigenous50:50
Raw materials available only from China15% to 18%
Permanent input cost increase from China vs pre-COVID10% to 15%
Specialty chemicals Brownfield revenue potential (full scale)~₹90 to 100 cr
New oncology formulation facility revenue potential~₹200 to 250 cr at full potential, in 1.5–2 years
New API products market potentialover ₹500 cr; current capacity for ~₹80 to 100 cr turnover
Customers who purchased at higher pricesmore than 90%